A lot have been said about the latest CC, so will not repeat (maybe) what has been said.
First of all, why the conference ?. I believe that NP was trying to ”firm up” the price of the stock by communicating his personal thoughts about it and, simultaneously, releasing some information.
I liked his (voice) demeanor, the quality of sound (finally) and the fact that he answered many questions at the end.
Apart from what has been widely discussed my takeaways:
1) There is a top-notch group of doctors “onboard” (Sacha, Rusconi, Linder, Patterson) , this yields credibility to the ongoing research in all areas.
2) Things are happening. There is advance in several fronts. P2 protocol for NASH (any other company would see the price jump like crazy with only this news), 1st patient for GvHD in October, exploring the possibility of Lero for Angiogenesis and Metastasis, founding from Gates foundation for PrEP, army involvement
3) NP sounded very optimistic: “Stunning data” (PrEP), “we will make history” (HIV), regarding deal “you will understand latter”.
4) The deal(s) are “live and kicking”, by what he said, they seem to be much closer. A surprise is that there are now apparently TWO companies (he said “a couple of”), therefore maybe he cannot talk as he cannot reveal any data as It can be taken as informing the other depending of which parameters he discloses (this is just my speculation). This usually happens when the negotiations are very advanced and down to details.
5) NP said that no money will be spend on the P2 of NASH and Colorectal Cancer (music to my ears) as “we need to be careful with the funding”. That is what I wanted to know, let’s bring HIV to completion and then tackle whatever comes our way.
6) New indication for Lero as complement for Keytruda & others as its “mode of operation” is complementary. This is a HUGE market if it can be tapped at all.
7) We are back to the $125K per year price tag ???. He used it for the example of Samsung value of Lero in stock.
In general, a very good call, IMHO. I am getting ready for the ride in the next few months.
First of all, why the conference ?. I believe that NP was trying to ”firm up” the price of the stock by communicating his personal thoughts about it and, simultaneously, releasing some information.
I liked his (voice) demeanor, the quality of sound (finally) and the fact that he answered many questions at the end.
Apart from what has been widely discussed my takeaways:
1) There is a top-notch group of doctors “onboard” (Sacha, Rusconi, Linder, Patterson) , this yields credibility to the ongoing research in all areas.
2) Things are happening. There is advance in several fronts. P2 protocol for NASH (any other company would see the price jump like crazy with only this news), 1st patient for GvHD in October, exploring the possibility of Lero for Angiogenesis and Metastasis, founding from Gates foundation for PrEP, army involvement
3) NP sounded very optimistic: “Stunning data” (PrEP), “we will make history” (HIV), regarding deal “you will understand latter”.
4) The deal(s) are “live and kicking”, by what he said, they seem to be much closer. A surprise is that there are now apparently TWO companies (he said “a couple of”), therefore maybe he cannot talk as he cannot reveal any data as It can be taken as informing the other depending of which parameters he discloses (this is just my speculation). This usually happens when the negotiations are very advanced and down to details.
5) NP said that no money will be spend on the P2 of NASH and Colorectal Cancer (music to my ears) as “we need to be careful with the funding”. That is what I wanted to know, let’s bring HIV to completion and then tackle whatever comes our way.
6) New indication for Lero as complement for Keytruda & others as its “mode of operation” is complementary. This is a HUGE market if it can be tapped at all.
7) We are back to the $125K per year price tag ???. He used it for the example of Samsung value of Lero in stock.
In general, a very good call, IMHO. I am getting ready for the ride in the next few months.
2
